{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-109580","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.349747+00:00","generated_at":"2026-05-16T20:39:25.762619+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Turn Therapeutics Q3 net loss $1.9M; enters global Medline PermaFusion deal","bullets":["Net loss of $1.9M ($0.07/share) vs $0.67M loss in Q3 2024; G&A surged to $1.75M on listing costs.","Cash and equivalents $3.11M at Sept 30, 2025, up from $0.87M at Dec 31, 2024.","Closed global supply/development/license agreement with Medline for PermaFusion platform.","Started trading on Nasdaq under TTRX on Oct 8, 2025; appointed two new board members.","Commenced clinical trial of topical IL-36/IL-31 inhibitor for eczema."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-109580","json":"https://secwatch.observer/filing/0001213900-25-109580.json","markdown":"https://secwatch.observer/filing/0001213900-25-109580.md","text":"https://secwatch.observer/filing/0001213900-25-109580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390025109580/0001213900-25-109580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390025109580/ea0265413-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:39:25.762619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}